WEEKS 1-4
Building the habit
Low starting dose. Establishing the morning routine. Most people don't notice dramatic changes yet.
All content on this page has been medically reviewed by: Hassan Thwaini, Clinical Pharmacist and Copywriter, Master of Pharmacy (MPharm) on 6 May, 2026. GPhC Registration: 2221320View profile
A new version of a familiar treatment
Wegovy tablets are an oral version of semaglutide - the same medicine as the Wegovy injection, just taken differently. Instead of a weekly injection, it's a daily tablet absorbed through your digestive system.
The mechanism is the same: it mimics a natural hormone that reduces appetite and helps regulate blood sugar, taken alongside diet and activity changes.1 Wegovy tablets aren't currently licensed in the UK.
How effective are Wegovy tablets?
In a 64-week clinical trial, OASIS 4 (307 adults living with obesity or are overweight with at least one weight-related condition), participants taking oral semaglutide 25mg alongside lifestyle support lost an average of 13.6% of their body weight, versus 2.2% with placebo.1
As with all weight loss treatments, individual results varied.
| Weight loss achieved | Semaglutide tablets¹ (25mg) | Placebo |
|---|---|---|
| ≥5% body weight loss | 76% | 31% |
| ≥10% body weight loss | 60% | 14% |
| ≥15% body weight loss | 47% | 6% |
| ≥20% body weight loss | 28% | 3% |
The Wegovy Pill and other weight loss medications
Although the Wegovy pill and injection contain the same active ingredient, clinical data suggests the injection produces greater average weight loss in obesity trials. The same is true of other anti-obesity injections compared to their oral equivalents.1-3
*Results are based on separate clinical trials and cannot be directly compared.
| Treatment | Study duration | Average weight loss |
|---|---|---|
| Semaglutide tablet (25mg daily)¹ | 64 weeks | 13.6% |
| Semaglutide injection (2.4mg weekly)² | 68 weeks | 14.9% |
| Tirzepatide injection (2.4mg weekly)³ | 72 weeks | 20.9% |
Can you get the Wegovy Pill in the UK?
Oral Wegovy is not currently available in the UK. Before becoming available, they would need approval from the Medicines and Healthcare products Regulatory Agency (MHRA). If approved, further guidance form NICE would determine availability.
While some estimates suggest availability could be considered in late 2026, there is no confirmed timeline. At present, Wegovy injections remain the only semaglutide formulation licensed for weight loss.
What to expect
The journey, in four steps
Oral GLP-1s builds over time. Here's how:
WEEKS 5-8
Appetite shifts
Appetite starts to reduce. Smaller portions feel satisfying. Dose typically increases during this phase.
WEEKS 8-16
Consistent progress
Most patients see steady, measurable weight loss. Titration continues toward maintenance dose.
WEEKS 16+
Full effect
At maintenance dose, weight loss continues. Most trials show full effect after a few months.
How Numan is preparing for the Wegovy Pill
Numan doesn't currently prescribe Wegovy Pills, and they're not available through our services. However, we closely monitor emerging clinical data and regulatory developments. If oral semaglutide is approved in the UK, it would undergo careful clinical review before being incorporated into any treatment pathway.
In the meantime, Numan provides access to licensed, MHRA-approved weight loss treatments alongside structured clinical supervision, regular monitoring, and behavioural support.
FAQs
Your questions answered
KNOWLEDGE
Learn more about our weight loss treatments
References
Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077–87.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.
Medically reviewed: